Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension

Clinics in Chest Medicine

Volumn 34, Issue 4, 2013, Pages 825-840

  McLaughlin, Vallerie V ^a   Palevsky, Harold I ^b  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

Epoprostenol; Iloprost; Inhaled therapy; Intravenous therapy; Parenteral therapy; Prostacyclins; Prostanoids; Treprostinil

Indexed keywords

ILOPROST; PLACEBO; PROSTACYCLIN; TREPROSTINIL;

ADVERSE OUTCOME; ASCITES; BLOODSTREAM INFECTION; CATHETER INFECTION; CATHETER THROMBOSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAINTNESS; FOOT PAIN; HEADACHE; HOT FLUSH; HUMAN; HYPOTENSION; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE PAIN; JAW PAIN; LEG PAIN; LUNG VASCULAR RESISTANCE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARADOXICAL EMBOLISM; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SORE THROAT; THROAT IRRITATION; THROMBOCYTOPENIA; WEIGHT REDUCTION;

EPOPROSTENOL; ILOPROST; INHALED THERAPY; INTRAVENOUS THERAPY; PARENTERAL THERAPY; PROSTACYCLINS; PROSTANOIDS; TREPROSTINIL;

ADMINISTRATION, INHALATION; ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; INFUSIONS, INTRAVENOUS;

EID: 84888203742     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.09.003     Document Type: Review

References (82)

1. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115(5):343-349.
2. Higenbottam T., Wheeldon D., Wells F., et al. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984, 1(8385):1046-1047.
3. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. NEngl J Med 1996, 334:296-301.
4. Christman B.W., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. NEngl J Med 1992, 327:70-75.
5. Humbert M., Morrell N.W., Archer S.L., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. JAm Coll Cardiol 2004, 43(12 Suppl S):13S-24S.
6. Tuder R.M., Cool C.D., Geraci M.W., et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999, 159(6):1925-1932.
7. Hoshikawa Y., Voelkel N.F., Gesell T.L., et al. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med 2001, 164(2):314-318.
8. McLaughlin V.V., McGoon M.D. Pulmonary arterial hypertension. Circulation 2006, 114(13):1417-1431.
9. Clapp L.H., Finney P., Turcato S., et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002, 26(2):194-201.
10. Best L.C., Martin T.J., Russell R.G., et al. Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets. Nature 1977, 267(5614):850-852.
11. McLaughlin V.V., Genthner D.E., Panella M.M., et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. NEngl J Med 1998, 338:273-277.
12. Jeffery T.K., Morrell N. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002, 45(3):173-202.
13. Fetalvero K.M., Martin K.A., Hwa J. Cardioprotective prostacyclin signaling in vascular smooth muscle. Prostaglandins Other Lipid Mediat 2007, 82(1-4):109-118.
14. Friedman R., Mears J.G., Barst R.J. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997, 96:2782-2784.
15. Boyer-Neumann C., Brenot F., Wolf M., et al. Continuous infusion of prostacyclin decreases plasma levels of t-PA and PAI-1 in primary pulmonary hypertension. Thromb Haemost 1995, 73(4):735-736.
16. Olschewski H., Rose F., Schermuly R., et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 2004, 102(2):139-153.
17. Fassina G., Tessari F., Dorigo P. Positive inotropic effect of a stable analogue of PGI2 and of PGI2 on isolated guinea pig atria. Mechanism of action. Pharmacol Res Commun 1983, 15(8):735-749.
18. Fontana M., Olschewski H., Olschewski A., et al. Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes. Br J Pharmacol 2007, 151(6):779-786.
19. Lambert O., Bandilla D. Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension. Drug Des Devel Ther 2012, 6:235-244.
20. Fuentes A., Coralic A., Dawson K.L. Anew epoprostenol formulation for the treatment of pulmonary arterial hypertension. Am J Health Syst Pharm 2012, 69(16):1389-1393.
21. Rubin L.J., Groves B.M., Reeves J.T., et al. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982, 66(2):334-338.
22. Rubin L.J., Mendoza J., Hood M., et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990, 112(7):485-491.
23. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med 2000, 132:425-434.
24. Shapiro S.M., Oudiz R.J., Cao T., et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. JAm Coll Cardiol 1997, 30:343-349.
25. McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002, 106:1477-1482.
26. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. JAm Coll Cardiol 2002, 40:780-788.
27. Robbins I.M., Gaine S.P., Schilz R.J., et al. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000, 117:14-18.
28. McLaughlin V.V., Genthner D.E., Panella M.M., et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999, 130:740-743.
29. Petitpretz P., Brenot F., Azarian R., et al. Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension. Circulation 1994, 89:2722-2727.
30. Aguilar R.V., Farber H.W. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000, 162(5):1846-1850.
31. Rosenzweig E.B., Kerstein D., Barst R.J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999, 99:1858-1865.
32. Kuo P.C., Johnson L.B., Plotkin J.S., et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997, 63:604-616.
33. Rich S., McLaughlin V.V. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. JAm Coll Cardiol 1999, 34:1184-1187.
34. Rubenfire M., McLaughlin V.V., Allen R.P., et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest 2007, 132(3):757-763.
35. Wade M., Baker F.J., Roscigno R., et al. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. JClin Pharmacol 2004, 44(1):83-88.
36. Wade M., Baker F.J., Roscigno R., et al. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. JClin Pharmacol 2004, 44(5):503-509.
37. Walkey A.J., Fein D., Horbowicz K.J., et al. Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension. Pulm Pharmacol Ther 2011, 24(4):421-425.
38. McSwain C.S., Benza R., Shapiro S., et al. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. JClin Pharmacol 2008, 48(1):19-25.
39. McLaughlin V.V., Gaine S.P., Barst R.J., et al. Efficacy and safety of treprostinil: an epoprostenol analogue for primary pulmonary hypertension. JCardiovasc Pharmacol 2003, 41(2):293-299.
40. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002, 165:800-804.
41. Barst R.J., Galie N., Naeije R., et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006, 28(6):1195-1203.
42. Sadushi-Kolici R., Skoro-Sajer N., Zimmer D., et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. JHeart Lung Transplant 2012, 31(7):735-743.
43. Oudiz R., Schilz R.J., Barst R.J., et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004, 126:420-427.
44. Skoro-Sajer N., Bonderman D., Wiesbauer F., et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. JThromb Haemost 2007, 5(3):483-489.
45. Lang I., Gomez-Sanchez M., Kneussl M., et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006, 129(6):1636-1643.
46. Vachiery J.L., Hill N., Zwicke D., et al. Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002, 121:1561-1565.
47. Skoro-Sajer N., Lang I.M., Harja E., et al. Aclinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension. Clin Pharm 2008, 47(9):611-618.
48. Tapson V.F., Gomberg-Maitland M., McLaughlin V.V., et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006, 129(3):683-688.
49. Gomberg-Maitland M., Tapson V.F., Benza R.L., et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005, 172(12):1586-1589.
50. Hiremath J., Thanikachalam S., Parikh K., et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. JHeart Lung Transplant 2010, 29(2):137-149.
51. Tapson V.F., McLaughlin V.V., Gomberg-Maitland M., et al. Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension. JVasc Access 2006, 7(3):112-117.
52. Ewert R., Halank M., Bruch L., et al. Acase series of patients with severe pulmonary hypertension receiving an implantable pump for intravenous prostanoid therapy. Am J Respir Crit Care Med 2012, 186(11):1196-1198.
53. Kallen A.J., Lederman E., Balaji A., et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol 2008, 29(4):342-349.
54. Kitterman N., Poms A., Miller D.P., et al. Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY(R). Mayo Clin Proc 2012, 87(9):825-834.
55. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration withthe American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. JAm Coll Cardiol 2009, 53(17):1573-1619.
56. Badesch D.B., Abman S.H., Simonneau G., et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007, 131(6):1917-1928.
57. Galie N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30(20):2493-2537.
58. Barst R.J., Gibbs J.S., Ghofrani H.A., et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. JAm Coll Cardiol 2009, 54(Suppl 1):S78-S84.
59. Doran A.K., Ivy D.D., Barst R.J., et al. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract 2008, (160):5-9.
60. Kingman M.S., Tankersley M.A., Lombardi S., et al. Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey. JHeart Lung Transplant 2010, 29(8):841-846.
61. Oudiz R.J., Farber H.W. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J 2009, 157(4):625-635.
62. Krause W., Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol 1986, 30(1):61-68.
63. John J., Palevsky H. Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension. Expert Rev Clin Pharmacol 2011, 4(2):197-205.
64. Beghetti M., Reber G., de M.P., et al. Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur Respir J 2002, 19(3):518-524.
65. Olschewski H., Walmrath D., Schermuly R., et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996, 124(9):820-824.
66. Sun Y.J., Xiong C.M., Shan G.L., et al. Inhaled low-dose iloprost for pulmonary hypertension: a prospective, multicenter, open-label study. Clin Cardiol 2011, 35(6):365-370.
67. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. NEngl J Med 2002, 347(5):322-329.
68. Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir Rev 2009, 18(111):29-34.
69. Hoeper M.M., Schwarze M., Ehlerding S., et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. NEngl J Med 2000, 342(25):1866-1870.
70. Opitz C.F., Wensel R., Winkler J., et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005, 26(18):1895-1902.
71. McLaughlin V.V., Oudiz R.J., Frost A., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006, 174(11):1257-1263.
72. Wilkens H., Guth A., Konig J., et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001, 104(11):1218-1222.
73. Channick R., Frantz R., Kawut S., et al. Amulticenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost. Pulm Circ 2013, 3:381-388.
74. Roman A., Barbera J.A., Escribano P., et al. Cost effectiveness of prostacyclins in pulmonary arterial hypertension. Appl Health Econ Health Policy 2012, 10(3):175-188.
75. Channick R.N., Voswinckel R., Rubin L.J. Inhaled treprostinil: a therapeutic review. Drug Des Devel Ther 2012, 6:19-28.
76. Voswinckel R., Reichenberger F., Gall H., et al. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm Pharmacol Ther 2009, 22(1):50-56.
77. Channick R.N., Olschewski H., Seeger W., et al. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. JAm Coll Cardiol 2006, 48(7):1433-1437.
78. Voswinckel R., Reichenberger F., Enke B., et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther 2008, 21(5):824-832.
79. McLaughlin V.V., Benza R.L., Rubin L.J., et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. JAm Coll Cardiol 2010, 55(18):1915-1922.
80. Benza R.L., Seeger W., McLaughlin V.V., et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. JHeart Lung Transplant 2011, 30(12):1327-1333.
81. de Jesus Perez V.A., Rosenzweig E., Rubin L.J., et al. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol 2012, 110(10):1546-1550.
82. Bourge R.C., Tapson V.F., Safdar Z., et al. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. Cardiovasc Ther 2013, 31(1):38-44.